Cure8 research brief
Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can help target stewardship where it matters most.
Hospital clinicians (gastroenterology, ID, surgery), antimicrobial stewardship teams, hospital administrators, IBD researchers, and concerned patients/caregivers.
This letter highlights a 10-year real-world analysis of inpatient antibiotic use in people hospitalized with IBD (2015–2024).
The authors report that while fewer admissions received any antibiotics in 2020–2024 versus 2015–2019, the intensity of antibiotic consumption (DDD per 100 bed-days) rose and use of broad-spectrum and last-resort agents such as carbapenems and vancomycin increased.
Antibiotic exposure was concentrated in older, higher-acuity admissions with longer stays and higher costs.
The authors argue stewardship should shift from counting exposed admissions to tracking intensity, escalation patterns, and indication-specific use, and propose an IBD-focused stewardship roadmap including diagnostic stewardship, standardized pathways for perioperative and intra-abdominal infections, early reassessment/de-escalation, and structured metrics.
The letter is grounded in the study’s abstract and frames stewardship implications rather than presenting new clinical trial data. It emphasizes monitoring antibiotic burden and targeted interventions to avoid unnecessary escalation while preserving outcomes.
Findings come from a real-world observational analysis and forecasting; the article proposes stewardship recommendations but does not present results of implemented interventions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
